ALLR
HEALTHCAREAllarity Therapeutics Inc
AI Insight
What's Moving ALLR Today?
No stock-specific AI insight has been generated for ALLR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.77$2.06
$1.32
Fundamentals
Market Cap$21M
P/E Ratio—
EPS$-0.70
Dividend Yield—
Dividend / Share—
ROE-87.9%
Profit Margin—
Debt / Equity—
Trading
Volume38K
Avg Volume (10D)—
Shares Outstanding15.9M
ALLR News
21 articles- Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?Yahoo Finance·Jun 19, 2026
- Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026Yahoo Finance·Jun 18, 2026
- Allarity Therapeutics Inc (ALLR) Revenue Breakdown: Business Segments, Regional Revenue & Profit ContributionTradingKey·Jun 18, 2026
- Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?Yahoo Finance·Jun 3, 2026
- Are Medical Stocks Lagging Bioventus (BVS) This Year?Yahoo Finance·May 18, 2026
- Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple CancersYahoo Finance·May 15, 2026
- Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in StockholmYahoo Finance·May 8, 2026
- Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing CampaignYahoo Finance·May 5, 2026
- Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark OfficeGlobeNewswire Inc.·Apr 27, 2026
- Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian CancerYahoo Finance·Apr 21, 2026
- Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate ProgressYahoo Finance·Mar 31, 2026
- Allarity closes $20M financing for stenoparib advancementYahoo Finance·Mar 7, 2026
- Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and CommercializationYahoo Finance·Mar 6, 2026
- Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet NeedYahoo Finance·Feb 18, 2026
- Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for EnrollmentYahoo Finance·Feb 3, 2026
- Allarity CEO says 2026 represents an ‘inflection point’Yahoo Finance·Jan 1, 2026
- Allarity Therapeutics Issues 2025 End of Year CEO Letter to ShareholdersYahoo Finance·Dec 31, 2025
- Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business UpdatesYahoo Finance·Nov 14, 2025
- Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 MonthsYahoo Finance·Sep 22, 2025
- Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025Yahoo Finance·Sep 17, 2025
- Sector Update: Health Care Stocks Higher Late AfternoonYahoo Finance·Aug 26, 2025
All 21 articles loaded
Price Data
Open$1.33
Previous Close$1.32
Day High$1.34
Day Low$1.30
52 Week High$2.06
52 Week Low$0.77
52-Week Range
$0.77$2.06
$1.32
Fundamentals
Market Cap$21M
P/E Ratio—
EPS$-0.70
Dividend Yield—
Dividend / Share—
ROE-87.9%
Profit Margin—
Debt / Equity—
Trading
Volume38K
Avg Volume (10D)—
Shares Outstanding15.9M
About Allarity Therapeutics Inc
Allarity Therapeutics A / S develops various therapeutic candidates for the treatment of cancer using complementary drug-specific diagnostics (cDx) generated by its drug response prediction technology. The company is headquartered in Horsholm, Denmark.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—